Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4649530
Max Phase: Preclinical
Molecular Formula: C30H37NO7
Molecular Weight: 523.63
Molecule Type: Unknown
Associated Items:
ID: ALA4649530
Max Phase: Preclinical
Molecular Formula: C30H37NO7
Molecular Weight: 523.63
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N1CCC([C@@]23C[C@@H](OC(=O)CO)[C@@](C)(O2)[C@@H]2CCC(C)=C2[C@@H]3OC(=O)/C=C/c2ccccc2)CC1
Standard InChI: InChI=1S/C30H37NO7/c1-19-9-11-23-27(19)28(37-25(34)12-10-21-7-5-4-6-8-21)30(22-13-15-31(16-14-22)20(2)33)17-24(29(23,3)38-30)36-26(35)18-32/h4-8,10,12,22-24,28,32H,9,11,13-18H2,1-3H3/b12-10+/t23-,24-,28+,29+,30-/m1/s1
Standard InChI Key: YZZRKVMSYAMVRQ-PDXYHNIYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 523.63 | Molecular Weight (Monoisotopic): 523.2570 | AlogP: 3.43 | #Rotatable Bonds: 6 |
Polar Surface Area: 102.37 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 13.13 | CX Basic pKa: | CX LogP: 2.48 | CX LogD: 2.48 |
Aromatic Rings: 1 | Heavy Atoms: 38 | QED Weighted: 0.35 | Np Likeness Score: 1.44 |
1. Wu Z, Suppo JS, Tumova S, Strope J, Bravo F, Moy M, Weinstein ES, Peer CJ, Figg WD, Chain WJ, Echavarren AM, Beech DJ, Beutler JA.. (2020) Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition., 11 (9): [PMID:32944138] [10.1021/acsmedchemlett.0c00186] |
Source(1):